Respira Labs is developing the first wearable device to measure “trapped air,” an early marker of Chronic Obstructive Pulmonary Disease (COPD). No reliable and validated methods currently exist to detect COPD exacerbations in time for early intervention and prevention. By leveraging the power of non-invasive acoustic sensors, audio signal processing, machine learning, and Acoustic Resonance Index Analysis (ARIA), our device will fundamentally revolutionize COPD management by predicting and preventing attacks at the patient’s home, significantly improving health outcomes and patient quality of life while dramatically lowering health care costs.
Total Funding: $1,000,000
Funding Stage: Funded
Business Stage: Scaling Up
Market: B2C, B2B
Company Size: 1 to 25
Founded: 2018
For AI/ML Startup Founders
Get introduced to VC/PE/CVC investors
For Investors at VC/PE firms
Get introduced to AI/ML Startup founders or founders at Respira Labs
